Nature

Reappraisal of HLA in Multiple Sclerosis: Close Linkage in Multiplex Families

Although association between multiple sclerosis (MS) and HLA-DR2, DQw6 has been well documented, family studies have not established linkage to HLA. Here we have (1) carried out an HLA-DQA1, -DQB1 ...
Medscape

Dirucotide Fails Primary End Point in Relapsing-Remitting MS

February 3, 2009 — BioMS is reporting that a phase 2 study of dirucotide in relapsing-remitting multiple sclerosis (RRMS) failed to meet primary end points of change in annualized relapse rates or ...
Nature

Epistatic effects occurring among susceptibility and protective MHC genes in IgA deficiency

A recent report from our group 3 indicated that there are distinct MHC susceptibility genes, located in different regions on different MHC haplotypes. On HLA-DR1- and -DR7-positive haplotypes, the ...
FierceBiotech

BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis

The interim analysis included patients from the first 200 to complete MAESTRO-01 and assessed the likelihood of the study reaching its primary endpoint at the end of the trial in MS patients with the ...
JSTOR Daily

Heritable Major Histocompatibility Complex Class II-Associated Differences in Production of Tumor Necrosis Factor α: Relevance to Genetic Predisposition to Systematic Lupus ...

This is a preview. Log in through your library . Abstract We report on the production of tumor necrosis factor (TNF)-α and TNF-β by mitogen-activated peripheral blood lymphocytes or enriched monocyte ...
FierceBiotech

BioMS Medical (MS.TO) Announces Positive Interim Analysis on Phase III Trial of Dirucotide (MBP8298) for Multiple Sclerosis

EDMONTON, Aug. 13 /PRNewswire-FirstCall/ - BioMS Medical Corp. , a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent ...